The expression of shared idiotypes (Slds) has been studied on malignant CD5' B cells from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) using a panel of 37 murine monoclonal antibodies previously demonstrated to be reactive with Slds derived from follicular B-cell lymphomas. Thirteen anti-Slds identified tumor cells from 31 of 105 (30%) CLL patients and 4 of 6 SLL patients. In comparison, the same panel of anti-Slds is reactive with 33% of follicular and diffuse B-cell lymphomas. Ten of these anti-Slds reacted with CLL cases at similar frequencies to -CELL NEOPLASMS express monoclonal surface im-
The expression of shared idiotypes (Slds) has been studied on malignant CD5' B cells from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) using a panel of 37 murine monoclonal antibodies previously demonstrated to be reactive with Slds derived from follicular B-cell lymphomas. Thirteen anti-Slds identified tumor cells from 31 of 105 (30%) CLL patients and 4 of 6 SLL patients. In comparison, the same panel of anti-Slds is reactive with 33% of follicular and diffuse B-cell lymphomas. Ten of these anti-Slds reacted with CLL cases at similar frequencies to -CELL NEOPLASMS express monoclonal surface im-B munoglobulins (Igs) whose variable (V) regions contain antigenic determinants termed idiotypes (Ids). Id determinants can either be unique to the particular Ig (private Ids) or can be shared between V regions of different Igs (shared Ids, SIds). Private Ids may serve as tumor-specific markers, and antibodies to private Ids (antiIds) have been used successfully to treat a variety of B-cell neoplasms.'-' However, anti-Id therapy has been hindered by the time required to make a customized antibody for each patient. The ready availability of anti-SIds should facilitate clinical study with these agents.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are malignancies of CD5' B cells.' Evidence suggests that CLL and SLL are malignant counterparts of a normal population of CD5' B cells that occur at low levels in adult lymph nodes and tonsils and fetal lymph nodes and spleens?" These cells may be involved in the regulation of the immune system.I3 CD5' B cells and the murine equivalent Ly-1' B cells are responsible for the production of autoreactive antibodies in both humans and mi~e.'~.'~ Recently we described 20 anti-SIds that reacted with 0.6% to 6.2% of B-cell lymphomas.16 With these anti-SIds and an additional 17 anti-SIds we tested the reactivity of tumor cells from 105 CLL cases and six SLL cases. In this report we describe the results of this testing and compare SId expression in CLL and SLL with other lymphomas.
MATERIALS AND METHODS

Patients.
One hundred and five patients with adult CLL were studied. Seventy-five percent of the patients were referred for immunophenotype determinants as part of a prospective study for the Cancer and Leukemia Group B (CALGB). All cases fulfilled the diagnostic criteria for CLL of the Chronic Leukemia-Myeloma Task Force." Peripheral blood lymphocytes from patients with CLL were separated from whole blood using Lymphoprep (Robbins Scientific, Mountain View, CA). Only CLL cases in which greater than 25% of the lymphocytes expressed monoclonal surface Ig were evaluated in our study. CLL patients had white blood cell counts ranging from 20,000 to 300,OOO/kL. Lymphoma specimens (including all cases of SLL) were obtained from patients referred to the University of California at San Diego (UCSD). Other lymphomas were screened by IDEC Pharmaceuticals Corp (Mountain View, CA) as part of a multicenter study. Lymphoma specimens were histopathologically classified according to the Internathat of the B-cell lymphomas. Two anti-Slds, which are known to react with autoantibodies, were significantly more prevalent in CLL than in B-cell lymphomas. These data confirm the presence of Slds in CLL and provide further evidence of an association between CLL and autoimmunity. The identification of a panel of antibodies reactive with a significant number of CLL and SLL patients will facilitate the application of anti-idiotype antibody therapy in these diseases.
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tional Working Formulation." Single cell suspensions were obtained from lymph node biopsies by mechanical dissociation. SLL patients had absolute lymphocyte counts of less than 5,5OO/kL. Lymphocytes were either stained after a 4-hour incubation at 37°C or cryopresewed in liquid nitrogen for later analysis.
Monoclonal antibodies (MoAbs) and antisera. Murine MoAbs were used as follows: TlOl (anti-CD5) (Hybritech Inc, San Diego, CA); B4 (anti-CD19) (Dana Farber Cancer Institute, Boston, MA); antihuman and antihuman A (AMAC, Westbrook, ME); B1 (anti-CD20) (Coulter Immunology, Hialeah, FL); T29/33 (anti-CD45) (Hybritech Inc). Secondary antisera were fluoresceinconjugated goat antimouse Ig (Coulter Immunology) and fluorescein-conjugated goat antirat Ig (TAGO Inc, Burlingame, CA). Ig isotypes were detected with fluorescein-conjugated, heavy chainspecific goat antisera (TAGO Inc).
Anti-SIds were made as previously described.16 Briefly, tumor Ig were isolated from tumor cells from patients with follicular small-cleaved lymphoma by a heterohybridoma fusion te~hnique.'~ Either mice or rats were immunized with purified tumor Ig and spleen cells were fused with the nonsecreting mouse myeloma line SP2/0 Ag 14. Anti-Ids were selected that reacted with the patient's tumor Ig but not with a panel of monoclonal Igs from other patients, which included some Igs of the same heavy and light chain type. Anti-SIds were then selected on the basis of inhibition of Id binding by normal human serum. Anti-SIds that reacted with serum Ig at concentrations ranging from 0.6 to 50 kg/mL were tested for reactivity with lymphoma biopsy specimens. Thirty-seven anti-SIds that reacted with tumors from more than one lymphoma patient were used to screen cells from 105 CLL patients and six SLL patients.
Indirect immunofluorescence was performed in 96-well microtiter plates (Dynatech Inc, Rochester, NY) as previously described?' Briefly, 1 x lo6 cells per test The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.
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For personal use only. on June 7, 2017. by guest www.bloodjournal.org From were incubated with primary antibody for 30 minutes at 4"C, washed three times with phosphate-buffered saline supplemented with 1% newborn calf serum, and incubated 30 minutes at 4°C in the appropriate secondary antibody. Cells were washed three more times, fixed in 0.75 mL of 1% formaldehyde, and stored in the dark at 4°C until analysis on an EPICS Profile flow cytometer (Coulter Electronics). The tumor clone was identified by light-chain analysis and CLL or SLL cases were considered SId-positive when greater than 50% of the tumor clone reacted with an anti-SId. The anti-SId was considered comprehensive in its reactivity if it reacted with 85% or more of the tumor clone. To compare the significance of differences in reactivity between different groups, Fisher's exact test was used to generate a two-tailed P value.
An enzyme-linked immunosorbent assay (ELISA) was used to determine SId concentration in patient sera as previously Briefly, anti-SIds were immobilized on 96-well microtiter plates and then incubated for 1 hour with dilutions of purified Id ranging from 312.5 ng/mL to 4.9 ng/mL or dilutions of serum samples from lymphoma patients or normal donors. The plates were then washed, treated with horseradish peroxidase-conjugated goat antihuman K or A light-chain antisera (TAG0 Inc), and the peroxidase reaction was developed with orthophenylene diamine-H,O, substrate (Sigma Chemical Co, St Louis, MO). Reactivity of patient sera was compared with that of normal human serum and an approximate serum Id level was determined from the standard curve.
Detection of Sld in serum.
RESULTS
Of the 105 CLL patients and six SLL patients screened, 12 of the anti-SIds identified 31 CLL cases (30%), and five anti-SIds identified four SLL cases (66%) ( Table 1 ). The monoclonal anti-SIds S2-33 and L46-49 reacted with tumor cells from the largest number of CLL patients, 7.6% and 6.7%, respectively. The remaining 10 anti-SIds reacted with tumor cells from 1.0% to 3.8% of CLL patients. A representative set of flow cytometry histograms from an SId' CLL patient is shown in Fig 1. Tumor cells from four CLL cases and one SLL case reacted with two anti-SIds. Of the CLL cases tested, 70 expressed K light chains and 35 expressed A light chains. Thirty-four percent of K clones reacted with one or more anti-SIds compared with 20% of A clones (P = .174). Table 2 compares the frequency of reactivity of the anti-SId panel with tumor cells from CLL and SLLpatients, and patients with follicular or diffuse non-Hodgkin's lymphomas. The panel's reactivity with 30% of CLL patients was similar to it's reactivity with follicular B-cell lymphomas (31%). The frequency of reactivity was also similar to that found for diffuse B-cell lymphomas (37%). However, if diffuse large cell lymphomas are separated out from other diffuse lymphomas, the anti-SId frequency of reactivity increases to 51%. The frequency of reactivity of the panel with SLL (66%) was twice that for CLL, but the number of SLL cases is too small to infer significance from this difference.
Individual anti-SId reactivities in CLL are compared with those in B-cell lymphomas in Table 3 . The anti-SIds L46-49 and L50-19 showed significantly higher reactivity with CLL cases than B-cell lymphoma cases (P = .0006 and P = .043, respectively). A third anti-SId, W15, reacted with more CLL cases than B-cell lymphoma cases and this difference was found to be marginally significant (P = .115). The remaining nine anti-SIds reactive in CLL did not show significant differences in frequency of reactivity between CLL and B-cell lymphoma cases. In addition, a number of anti-SIds reactive with B-cell lymphomas have not yet demonstrated reactivity in CLL.
An ELISA to measure serum SId levels is demonstrated in Fig 2. Serial dilutions of serum from a representative Fluorescence Intensity 
DISCUSSION
We have demonstrated that 30% of CLL cross-react with antibodies to shared idiotypes generated against low-grade follicular B-cell lymphomas.16 The majority of SIds on CLL cells are expressed at similar frequencies on lymphoma cells. However, two anti-SIds reacted with significantly more CLL cases than lymphoma cases.
One anti-SId, L46-49, identified 6.7% of CLL cases compared with 0.6% of B-cell lymphomas (P = .0006) and also has been found to react with SIds that are expressed by human anti-DNA autoantibodies in patients with systemic lupus erythematosus (SLE) (R.S. Schwartz, personal communication, April 1990). The other anti-SId, L50-19, reacted with tumor cells from 3.8% of CLL tested but only 0.7% of B-cell lymphomas (P = .043) and is reactive with rheumatoid factor and with anti-DNA autoantibodies?'
Carson and F o n e identified an MoAb, 17.109, which reacted with an SId present on over one third of all human IgM rheumatoid factor paraproteins. Kipps et aIz4 demonstrated that 17.109 also reacted with over 20% of CLL K-expressing clonesz4 but rarely with CD5-B-cell lymphomas.= It was later established that 17.109 recognized a K light chain variable region encoded by the germline sequence Vk325 (also termed V,RF).'6 Based on these data, Kipps hypothesized that CLL may express a limited number of variable region genes that undergo little or no somatic mutation.26 L46-49 and L50-19 seem to be similar to 17.109 in identifying an autoantibody-associated SId that is significantly more common in CLL than in other B-cell neoplasms.
CD5' B cells have been associated with the production of autoantibodies in normal individuals as well as patients with autoimmune disease^.'^-'^ Relatives of CLL patients are more likely to develop CLL and are even more likely to manifest some type of autoimmune disease.*' The finding that certain antibodies such as L46-49, L50-19, and 17.109
For Anti-SIds may represent an important advance in the field of anti-Id therapy. A library of anti-SIds will facilitate the use of antibodies as diagnostic and therapeutic agents in the management of B-cell neoplasms. If anti-SIds identify proteins encoded by nonmutating germline genes, they may obviate the problem of idiotype escape.' Additionally, if CLL and SLL lack the capacity for somatic hypermutation,32,33 then these diseases may be particularly suitable for anti-Id therapy.
Ideal patients for anti-Id therapy have low levels of circulating Id and have tumor cells that bind comprehensively with the anti-Id. Figures 2 and 3 demonstrate that a representative SLL patient can meet these criteria with an anti-SId, despite the fact that anti-SIds show reactivity with normal serum. Based on light-chain analysis, 100% of the tumor clone reacted with the anti-SId (Fig 3) . Figure 2 shows that the patient serum had less reactivity with the anti-Sld than normal human serum and, therefore, conmas. 26, 32, 33 For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From tained minimal levels of circulating tumor Id. More importantly, both the patient serum and normal human serum contained less than 10 Fg/mL of SId, fulfilling the therapeutic requirement for low levels of circulating SId.
The screening of CLL with 37 anti-SIds made to follicular B-cell lymphomas showed several important trends. The anti-SId panel's frequency of reactivity with CLL was similar to that with B-cell lymphomas. The preferential reactivity with CLL cases of L46-49 and L50-19, anti-SIds that also react with autoantibodies, strengthens the link between CLL and autoimmunity. CLL cases will be screened with additional anti-SIds, including those generated against CLL, to further evaluate the extent of the differences in SId expression between CLL and other B-cell neoplasms. Additional SLL patients will also need to be screened to evaluate the differences between CLL and SLL. The availability of a panel of anti-SIds that react with a significant percentage of CLL and SLL patients will facilitate the use of anti-Id in the diagnosis and treatment of these two malignancies.
